Back to search results

A Study of RO7566802 for Advanced Solid Tumors

This study is testing a new drug called RO7566802, both by itself and in combination with another drug called atezolizumab. It's for people aged 18 and older with locally advanced, recurrent, or metastatic (spread to other parts of the body) solid tumors that have progressed after standard treatments. The main goals are to see how safe the drugs are and what side effects they might cause. Researchers will also look at how the body handles the drugs and if they show any signs of helping to fight the cancer. This study is currently unclear on its recruitment status and plans to enroll about 65 participants.

Study design
This is a first-in-human, open-label study, meaning you and your doctors will know which treatment you are receiving. It will enroll about 65 participants in two stages: dose escalation and expansion.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be monitored for side effects for up to approximately 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06031441

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Genentech, Inc.
~65 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:RO7566802Atezolizumab

At a glance

Recruiting sites
0 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Dose-limiting Toxicity (DLTs)
Measured over Cycle 1 Day 1 through 21 days after Cycle 2 Day 1 (Cycle length=21 days) (up to approximately 42 days)
+1 more outcome measured

Conditions

Locally Advanced Solid Tumors
Recurrent Solid Tumors
Metastatic Solid Tumors

Explore related trials

Solid Neoplasm

NCT06031441

Where you'd take part

This study runs at 18 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Addenbrooke's Hospital

    Cambridge, United Kingdomno site contact published

  • British Columbia Cancer Agency - 600 10th Ave W

    Vancouver, British Columbia, Canadano site contact published

  • Churchill Hospital

    Oxford, United Kingdomno site contact published

  • Icahn School of Medicine at Mount Sinai (ISMMS)

    New York, New Yorkno site contact published

  • Leicester Royal Infirmary

    Leicester, United Kingdomno site contact published

  • Magee-Woman's Hospital

    Harrisburg, Pennsylvaniano site contact published

  • National Cancer Centre

    Singapore, Singaporeno site contact published

  • National University Hospital

    Singapore, Singaporeno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Trials · STUDY_DIRECTOR · Hoffmann-La Roche

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Life expectancy \>=3 months, in the investigator's judgment
Adequate hematologic and end-organ function
Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care
Measurable disease per RECIST v1.1
Tumor specimen availability, for certain cohorts

Exclusion

Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions
Active hepatitis B or C
Active tuberculosis
Positive test for human immunodeficiency virus (HIV) infection
Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Active or history of autoimmune disease
Prior allogeneic stem cell or organ transplantation
Uncontrolled tumor-related pain
Significant cardiovascular disease

What this trial measures

  • Number of Participants with Dose-limiting Toxicity (DLTs)Cycle 1 Day 1 through 21 days after Cycle 2 Day 1 (Cycle length=21 days) (up to approximately 42 days)
  • Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)Up to approximately 4 years